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Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) is a novel disease caused by a gain-of-function
mutation in the V2 vasopressin receptor (V2R), which results in water overload and hyponatremia. We report the
effect of water loading in a 3-year old boy with NSIAD, diagnosed in infancy, to assess urine aquaporin-2 (AQP2)
excretion as a marker for V2R activation, and to evaluate the progression of the disease since diagnosis. The patient
is one of the first known NSIAD patients and the only patient with a R137L mutation. Patient underwent a
standard water loading test in which serum and urine sodium and osmolality, serum AVP, and urine AQP2
excretion were measured. The patient was also evaluated for ad lib fluid intake before and after the test. This
patient demonstrated persistent inability to excrete free water. Only 39% of the water load (20 ml/kg) was excreted
during a 4-hour period (normal ≥ 80-90%). Concurrently, the patient developed hyponatremia and serum
hypoosmolality. Serum AVP levels were detectable at baseline and decreased one hour after water loading;
however, urine AQP2 levels were elevated and did not suppress normally during the water load. The patient
remained eunatremic but relatively hypodipsic during ad lib intake. In conclusion, this is the first demonstration in
a patient with NSIAD caused by a R137L mutation in the V2R that urine AQP2 excretion is inappropriately elevated
and does not suppress normally with water loading. In addition, this is the first longitudinal report of a pediatric
patient with NSIAD diagnosed in infancy who demonstrates the ability to maintain eunatremia during ad lib
dietary intake.
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Introduction
Normal fluid balance requires an intact thirst mechan-
ism and normal free water excretion by the kidneys,
mediated by arginine vasopressin (AVP), also known as
antidiuretic hormone (ADH). AVP exerts its antidiuretic
action via the V2 vasopressin receptor (V2R) in the
basolateral membrane of renal collecting duct cells.
Binding and activation of the V2R, a G-protein coupled
receptor (GPCR), increases intracellular cAMP and
mediates shuttling of the water channel aquaporin-2
(AQP2) from cytosolic storage vesicles to the apical
membrane of collecting duct cells, resulting in increased
water permeability and antidiuresis [1]. A fraction of
this AQP2 is excreted in the urine and has been found
to be a useful marker of V2R activity [2]. Water loading
in a normal individual suppresses plasma AVP levels
and attenuates antidiuresis as a result of decreased
AQP2 shuttling to the apical membrane of collecting
duct cells. Consequently, less AQP2 is shed into the
urine [3,4].
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impaired water excretion mediated by gain-of-function
mutations in the X-linked gene for V2R in two unrelated
male infants who presented with irritability or seizures
and hyponatremia [5]. Their clinical and laboratory find-
ings were consistent with the syndrome of inappropriate
secretion of antidiuretic hormone (SIADH) yet their AVP
levels were undetectable. We have termed this condition
“nephrogenic syndrome of inappropriate antidiuresis”
(NSIAD). Each patient carries a missense mutation in
codon 137 of AVPR2, which results in a change from
arginine to cysteine (R137C) in one patient and to leucine
(R137L) in the other [5]. Codon 137 is part of a highly
conserved DRY/H motif located at the junction of the
third transmembrane domain and the second intracellu-
lar loop of class 1 GPCRs. This motif is critical for G-
protein coupling [6] and the two mutations each resulted
in a constitutively active V2R [5].
Since our initial description of NSIAD, many reports
from around the world, including individual and family
studies, have characterized the clinical course of this syn-
drome [7-12]. All of these patients have the R137C V2R
mutation. Here we report the clinical course of the only
known patient with NSIAD caused by the more potent
R137L V2R mutation [5]. This patient demonstrated the
ability to maintain eunatremia during ad lib dietary
intake. However, urine AQP2 levels were elevated and
did not suppress normally during a standard water load-




CS first presented at 2.5 months of age with seizures and
hyponatremia (118-120 mmol/L). His laboratory studies
suggested SIADH; however, he had undetectable AVP
levels on repeated occasions. DNA sequencing revealed a
missense mutation in his AVPR2 gene, resulting in a
R137L gain-of-function mutation of the V2R [5]. Fluid
restriction and oral urea resulted in eunatremia and nor-
mal growth and development. The patient was lost to fol-
low-up between age 20-32 months, during which time
urea was given only intermittently and ultimately discon-
tinued by the family at age 30 months. Despite inconsis-
tent or complete lack of intake of urea, periodic
measurements of serum sodium concentration by his
pediatrician were always within the normal range. He was
admitted to our institution at age 36 months to assess his
water metabolism and to determine need for ongoing urea
treatment.
Water loading test
A water loading test [4,13,14] was performed in the Pedia-
tric Clinical Research Center at our institution. A
peripherally-inserted central catheter and a Foley catheter
were placed 24 hours prior to the test. The patient was
monitored without fluid restriction for 24 hr. Baseline
urine and blood were collected at 60 and 30 minutes prior
to administration of water [20 mL/kg (360 mL) over 30
minutes via nasogastric tube]. Urine and blood samples
were collected every 30 and 60 minutes, respectively, for 4
hours for measurement of sodium and osmolality. In addi-
tion, serum AVP (Quest diagnostics) [5] and urine AQP2,
creatinine, and urine volume were measured. After the
test, the patient was observed on ad libitum dietary intake.
Intake and output were monitored for an additional 72
hours. Of note, the same reference laboratory for serum
AVP measurement was used throughout this child’sl i f e .
Preparation of urine samples for urinary AQP2 analysis
Urine samples were centrifuged at 4,000 g for 5 min to
remove any debris. The supernatant was diluted 1:1 with 2
× sodium dodecyl sulfate (SDS) sample buffer containing
2-mercaptoethanol. The samples were heated for 15 min
at 65°C and stored at -20°C until analyzed. Just before
loading for electrophoresis, samples were warmed to 37°C.
Development of AQP2 antibody
As described previously [15], a rabbit polyclonal antibody
against AQP2 was prepared by Gene-med Biotechnologies
Inc., (San Francisco, CA, USA) using a synthetic peptide
(VELHSPQSLPRGSKA) from the COOH terminus of
AQP2 [16]. The peptide was conjugated to keyhole limpit
hemocyanin (KHL) by a cystein sulfhydryl linkage. Test
bleedings were screened by ELISA. Final titers were
reported to be > 100,000. In western blot analysis, the
AQP2 antibody showed no reactivity to BSA.
Urine AQP2 western blot
AQP2 peptide was conjugated to BSA using the Imject
Immunogen EDC conjugation kit (Pierce, Rockford, IL,
USA). The AQP2 peptide conjugated BSA (AQP2-BSA) at
varying concentrations and 10 μl of the patient’ss a m p l ea t
each time point were resolved on a 12% SDS-polyacryla-
mide gel and transferred to a polyvinylidine difluoride
membrane. The membrane was incubated with the rabbit
anti-human AQP2 antibody at 4°C overnight, washed, and
incubated with anti-rabbit IgG horseradish peroxidase
antibody (Amersham, Piscataway, NJ, USA) [15]. Immu-
noreactive bands were visualized by enhanced chemilumi-
nescence (NEN Life Science). The bands of the AQP2-
BSA standards and the nonglycosylated form of AQP2 on
the film were scanned and analyzed using NIH image
software.
Calculation of urinary AQP2 excretion
After densitometry measurements, a standard curve was
constructed of known amounts of AQP2-BSA versus
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surements of the urine samples were converted to a
numerical value calculated from the curve (Prism,
Graph Pad, San Diego, CA, USA). Numerical values
were reported as pmol/mg creatinine. In initial studies,
concentrations of AQP2 peptide conjugated BSA
included 10, 20, 30, and 50 ng [15]. However, with these
concentrations of AQP2-BSA, the patient’s samples for
urine AQP2 were too high to accurately measure.
Repeat immunoblots were performed with AQP2-BSA
at 50, 100, 150, and 200 ng as described above.
Results
Pre-water loading test
As initially reported at the time of NSIAD diagnosis,
serum AVP was undetectable with concurrent hyponatre-
mia, serum hypoosmolality, and inappropriately concen-
trated urine (Table 1). Following initiation of water
restriction and urea treatment [17], serum sodium and
osmolality normalized, associated with measurable serum
A V Po f5 . 5p g / m L( T a b l e1 ) .D e s p i t ead libitum fluid
intake and subsequent discontinuation of urea, these
values remained normal (Table 1).
Water loading test
Prior to the water loading test, the patient’ss e r u m
sodium concentration was 135 mmol/L, and serum and
u r i n eo s m o l a l i t yw e r e2 8 3mmol/L and 857 mmol/kg,
respectively. An hour after the 20 mL/kg water load,
serum sodium was 128 mmol/L, and serum and urine
osmolality were 272 mmol/L and 709 mmol/kg, respec-
tively (Table 2). Over the next three hours, his serum
sodium concentration remained stable and was 127
mmol/L at the conclusion of the test, at which time his
serum osmolality had decreased to 267 mmol/L. Urine
osmolality was inappropriately increased to 884 mmol/
kg, exceeding the baseline value. Of note, serum AVP
was 2.6 pg/mL at baseline and decreased to 1.1 pg/mL by
one hour after water loading. Urine output during the 4-
hour test was 140 mL, which was only 39% of the water
load (normal ≥ 80-90% of the water load).
Intake and output during ad lib fluid intake
During the subsequent 3 days following the water load-
ing test, the patient had free access to liquid based on
his thirst. His daily intake was between 50-55 mL/kg/24
h (normal fluid intake for weight is 75-80 mL/kg/24 h)
[18] whereas his 24 hour urine output remained at 30-
35 mL/kg/24 hr. His serum sodium concentration was
maintained between 131 and 139 mmol/L during this
time.
Urine aquaporin 2
Quantitative immunoblot assay for urine AQP2 showed
an abnormally elevated baseline of 420 pmol/mg Cr,
which did not suppress normally for at least 3 hr after
water loading (87-98% of baseline, where normal is 5-
17% of baseline) [15] (Figures 1, 2). The AQP2-BSA
standard curve for densitometry measurement is shown
in Figure 3 [5].
Discussion
This is the first demonstration in a patient with NSIAD
caused by the R137L V2R mutation of urinary AQP2
excretion which was markedly elevated at baseline and
which did not suppress normally in a standard water
loading test. Our patient’s baseline urine AQP2 excre-
tion exceeded that seen in normal adults following 12
hours of water deprivation (7-24 pmol/mg creatinine;
personal communication, F. Umenishi), a condition
known to increase urine AQP2 excretion [3]. These
findings of increased urinary AQP2 in our patient are
consistent with a gain of function mutation in V2R.
Persistent urinary excretion of AQP2 during water
loading has been reported in one patient with NSIAD
[12] caused by the less potent R137C mutation [5]. In
Table 1 Serum sodium (Na) concentration, serum osmolality (Osm), serum AVP, and urine osmolality from initial
evaluation at 2.5 months to 3 years of age












2.5 m Initial presentation 118 247 < 1 390
5.5 m After 1 month of water restriction and urea 142 295 5.5 n/a*
3 yr Off urea for > 6 months; ad lib intake 139 295 3.1 628
*n/a = not available
Table 2 Serum sodium, serum osmolality, and urine
osmolality during standard water loading test (20 mL/kg)













-60 135 283 857
+60 128 272 709
+120 128 266 753
+180 128 268 842
+240 127 267 884
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described in several human diseases of pathological AVP
secretion. A decrease or increase in urinary AQP2 levels
was shown to correspond with diminished or exagger-
ated levels of AVP, as seen in central diabetes insipidus
or SIADH, respectively [3,4]. In normal individuals,
w a t e rl o a d i n gr e d u c e sa n t i d i u r e s i sa n d ,a se x p e c t e d ,
urine AQP2 levels [3,15]. In studies of water loading in
normal adults, urine AQP2 excretion at 2 hours after an
oral water load of 20 mL/kg was reduced to 10% of
baseline [15]. In the absence of appropriate diuresis dur-
ing water loading, NSIAD patients would be predicted
to have persistently elevated urine AQP2 levels. This is
demonstrated in the R137C V2R mutation patient who
received 50% of a standard water load [12] and con-
firmed by the results of our patient, who received the
standard water load, in which urine AQP2 levels did not
suppress normally, falling to only 87-98% of baseline for
up to 3.5 hours after water loading.
The patient’s serum AVP levels merit discussion. AVP
levels were undetectable (< 1 pg/ml) on initial presentation
with hyponatremia during infancy, leading us to the iden-
tification of an activating V2R mutation [5]. Following
normalization of the patient’s hydration status with fluid
restriction and oral urea supplementation, AVP levels
were in the normal range (5.5 pg/ml). AVP levels were
again in the normal range (3.1 pg/ml) 6 months following
self-discontinuation of urea, associated with eunatremia
and hypodipsia. Furthermore, during the water loading
challenge, serum AVP levels decreased from a baseline of
2.6 pg/mL to 1.1 pg/mL, the approximate assay limit of
detectability, by one hour, when the patient had developed
hyponatremia and serum hypoosmolality. Water loading
in a patient with R137C mutation also resulted in low but
detectable serum AVP level [10]. Thus, despite the pre-
sence of a constitutively active V2R, these results indicate
appropriate regulation of AVP secretion in NSAID. Possi-
ble explanations for the low but detectable AVP levels fol-
lowing water loading in NSIAD include contamination
with platelet-bound AVP [19] and/or a slight vasovagal sti-
mulus that may have exerted a non-osmotic effect that
resulted in an incomplete suppression of AVP secretion.
It is noteworthy that this patient demonstrated an
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Figure 1 Western immunoblot showing urine AQP2 excretion from 60 minutes prior to 240 minutes following oral water load. AQP2-
BSA standards included 50, 100, 150, and 200 ng.
Figure 2 Quantitative assessment of nonglycosylated AQP2
excretion in pmol/mg creatinine from 60 minutes prior to 240
minutes following oral water load. Sample values for the patient
were corrected for urinary creatinine.
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mmol/L range under ad lib conditions. His relative
basal eunatremia is likely a consequence of a diet that is
no longer exclusively liquid and is in marked contrast to
the severe hyponatremia observed at initial presentation,
when the infant was exclusively formula-fed. From a
dietary standpoint, our results concur with a previous
report in which a child with NSIAD, diagnosed retro-
spectively, remained eunatremic after transition to solid
food and discontinuation of sodium supplementation
[7,8,11].
An individual with NSIAD may escape detection during
infancy if the activating V2R mutation is mild and/or if
overhydration sufficient to induce hyponatremia does not
occur. A report by Decaux et al. of a large pedigree of
NSIAD patients caused by the R137C mutation in V2R
highlights the marked variability in clinical presentation of
this disorder [9]. One affected hemizygous male was
apparently asymptomatic throughout life, and was discov-
ered only after being administered a water loading test.
Similarly, two other hemizygous adult males were discov-
ered only when their 8 week old nephew was diagnosed
with the disease and genetic testing was performed on the
family [8]. One of the adult males was completely asymp-
tomatic throughout his life and the other apparently has
had generalized tonic-clonic seizures early in life of
unknown etiology. In addition, several heterozygous
females demonstrated inappropriate antidiuresis during
water loading [8,10,12]. Thus, NSIAD may be more preva-
lent in the general population than would have otherwise
been predicted based on the relatively small number of
patients diagnosed in infancy.
In conclusion, this is the first report that urinary AQP2
levels in a patient with NSIAD caused by the R137L V2R
mutation are elevated at baseline and do not suppress
appropriately in response to water loading. This study
demonstrates that urinary AQP2 can be a useful marker
of V2R activity in NSIAD. Thus, increased urinary AQP2
excretion, in the setting of euvolemic hyponatremia and
low or undetectable levels of serum AVP, suggests the
possibility of NSIAD. This diagnosis should be confirmed
by sequencing of AVPR2.
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